Literature DB >> 16344461

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Eiichi Sato1, Sara H Olson, Jiyoung Ahn, Brian Bundy, Hiroyoshi Nishikawa, Feng Qian, Achim A Jungbluth, Denise Frosina, Sacha Gnjatic, Christine Ambrosone, James Kepner, Tosin Odunsi, Gerd Ritter, Shashikant Lele, Yao-Tseng Chen, Haruo Ohtani, Lloyd J Old, Kunle Odunsi.   

Abstract

In a recent report, [Zhang et al. (2003) N. Engl. J. Med. 348, 203-213], the presence of CD3+ tumor-infiltrating lymphocytes (TILs) was found to correlate with improved survival in epithelial ovarian cancer. We performed immunohistochemical analysis for TILs and cancer testis antigens in 117 cases of epithelial ovarian cancer. The interrelationship between subpopulations of TILs and expression of cancer testis antigens was investigated, as well as between TILs and overall survival. The median follow-up of the patients was 31 months. Patients with higher frequencies of intraepithelial CD8+ T cells demonstrated improved survival compared with patients with lower frequencies [median = 55 versus 26 months; hazard ratio = 0.33; confidence interval (C.I.) = 0.18-0.60; P = 0.0003]. No association was found for CD3+ TILs or other subtypes of intraepithelial or stromal TILs. However, the subgroups with high versus low intraepithelial CD8+/CD4+ TIL ratios had median survival of 74 and 25 months, respectively (hazard ratio = 0.30; C.I. = 0.16-0.55; P = 0.0001). These results indicate that CD4+ TILs influence the beneficial effects of CD8+ TIL. This unfavorable effect of CD4+ T cells on prognosis was found to be due to CD25+ forkhead box P3 (FOXP3)+ regulatory T cells (Treg; suppressor T cells), as indicated by survival of patients with high versus low CD8+/Treg ratios (median = 58 versus 23 months; hazard ratio = 0.31; C.I. = 0.17-0.58; P = 0.0002). The favorable prognostic effect of intraepithelial CD8+ TILs did not correlate with concurrent expression of NY-ESO-1 or MAGE antigens. We conclude that intraepithelial CD8+ TILs and a high CD8+/Treg ratio are associated with favorable prognosis in epithelial ovarian cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16344461      PMCID: PMC1311741          DOI: 10.1073/pnas.0509182102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.

Authors:  K Schumacher; W Haensch; C Röefzaad; P M Schlag
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Authors:  E Y Woo; C S Chu; T J Goletz; K Schlienger; H Yeh; G Coukos; S C Rubin; L R Kaiser; C H June
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

3.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

4.  Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4.

Authors:  C Landry; F Brasseur; G C Spagnoli; E Marbaix; T Boon; P Coulie; D Godelaine
Journal:  Int J Cancer       Date:  2000-06-15       Impact factor: 7.396

Review 5.  Ovarian cancer: epidemiology, biology, and prognostic factors.

Authors:  C H Holschneider; J S Berek
Journal:  Semin Surg Oncol       Date:  2000 Jul-Aug

6.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

Authors:  M E Christine Lutsiak; Roshanak T Semnani; Roberto De Pascalis; Syed V S Kashmiri; Jeffrey Schlom; Helen Sabzevari
Journal:  Blood       Date:  2004-12-09       Impact factor: 22.113

7.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

8.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Authors:  C G Clemente; M C Mihm; R Bufalino; S Zurrida; P Collini; N Cascinelli
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

9.  New paths in human cancer serology.

Authors:  L J Old; Y T Chen
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

10.  MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue.

Authors:  A M Gillespie; S Rodgers; A P Wilson; J Tidy; R C Rees; R E Coleman; A K Murray
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more
  965 in total

1.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 2.  HIF transcription factors, inflammation, and immunity.

Authors:  Asis Palazon; Ananda W Goldrath; Victor Nizet; Randall S Johnson
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 3.  Epithelial ovarian cancer - more data, more questions?

Authors:  Stefanie Aust; Dietmar Pils
Journal:  Wien Med Wochenschr       Date:  2014-11-13

4.  Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.

Authors:  Eiman Adel Hasby
Journal:  Pathol Oncol Res       Date:  2011-12-08       Impact factor: 3.201

Review 5.  Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?

Authors:  Martin J Cannon; Hannah Goyne; Pamela J B Stone; Maurizio Chiriva-Internati
Journal:  Expert Opin Biol Ther       Date:  2011-01-28       Impact factor: 4.388

6.  Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.

Authors:  Hong Qiu; Patrick M Zmina; Alex Y Huang; David Askew; Barbara Bedogni
Journal:  Cancer Lett       Date:  2018-07-21       Impact factor: 8.679

7.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

8.  Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.

Authors:  Robyn D Gartrell; Douglas K Marks; Emanuelle M Rizk; Margaret Bogardus; Camille L Gérard; Luke W Barker; Yichun Fu; Camden L Esancy; Gen Li; Jiayi Ji; Shumin Rui; Marc S Ernstoff; Bret Taback; Sarabjot Pabla; Rui Chang; Sandra J Lee; John J Krolewski; Carl Morrison; Basil A Horst; Yvonne M Saenger
Journal:  Clin Cancer Res       Date:  2019-01-15       Impact factor: 12.531

9.  Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity.

Authors:  Diana A Alvarez Arias; Hye-Jung Kim; Penghui Zhou; Tobias A W Holderried; Xuan Wang; Glenn Dranoff; Harvey Cantor
Journal:  Cancer Immunol Res       Date:  2013-12-31       Impact factor: 11.151

Review 10.  Immunotherapy in ovarian cancer.

Authors:  Gina M Mantia-Smaldone; Bradley Corr; Christina S Chu
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.